# ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406

- Link: https://www.thailand-business-news.com/pr-news/arkbio-completes-all-cohort-dosing-in-australian-phase-i-trial-with-influenza-afc-drug-ak0406
- Published: 2026-07-24T08:00:00+07:00
- Author: PR Newswire

|   |

SHANGHAI, July 24, 2026 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. ("
ArkBio") today announced that all cohorts of healthy volunteers have been dosed 
in an Australian Phase I trial with AK0406, a novel long-acting antiviral-Fc conjugate(
AFC) drug for influenza prophylaxis. The clinical trial has now entered the follow‑
up phase.

 [](https://mmx.prnasia.com/media/MS1891897/ArkBio-Logo_original.jpg?id=OA2781261&p=medium600)

AK0406 is a novel long-acting antiviral agent developed by ArkBio. By precisely 
conjugating highly potent antiviral drugs to an antibody Fc fragment, AK0406 is 
designed to provide sustained pre- and post-exposure prophylaxis and potential therapeutic
benefits to public population, addressing the unmet needs for influenza prevention.
Preclinical data show that AK0406 exhibits broad-spectrum high-potent activity against
both influenza A and B viruses, retains Fc-mediated effector functions, and provides
prolonged protective effect. AK0406 has been optimized to offer an ideal pharmacological
profile for both prophylaxis and treatment of influenza infection.

Influenza remains a critical global public health challenge. Current preventive 
measures, such as seasonal vaccines, face limitations of antigenic drift, uncertainty
in strain prediction, and reduced protective efficacy among elderly and immunocompromised
populations. As a new generation of AFC drug, AK0406 has the promise to deliver 
a safer, more effective, and convenient innovative solution for influenza prevention
globally.

**About ArkBio**

ArkBio is a commercial-stage biotechnology company focused on the discovery and 
development of innovative therapeutics for respiratory/lung and pediatric diseases.
Founded in 2014, the company has established proprietary technology platforms and
a differentiated R&D pipeline through internal innovation and strategic collaborations.

Key clinical pipeline assets include: ziresovir (AK0529), the first direct-acting
antiviral for RSV with positive pivotal phase 3 results; AK3280, a potentially best-
in-class anti-fibrotic drug with positive phase 2 results in idiopathic pulmonary
fibrosis, which advances into a pivotal phase 3 trial; AK0901, a new generation 
ADHD drug that has been approved and commercialized in China for the treatment of
pediatric and adult ADHD. ArkBio has other first-in-class or best-in-class innovative
drug candidates in clinical or preclinical development.

ArkBio has established strategic partnerships with multinational and domestic pharmaceutical
companies including Roche, Genentech, Qilu Pharmaceutical, and leading academic 
institutions such as Scripps Research and the Institute of Microbiology of the Chinese
Academy of Sciences, as well as other domestic and international biotech companies
and CROs, for drug discovery and development.

For more information, please visit: [www.arkbiosciences.com](http://www.arkbiosciences.com/)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406 ](http://www.prnasia.com/story/archive/5010893_AE10893_0?rand=184833)